Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5874038 | 0.83 | ADORA3 (0.62) | FDPSCNR2ADORA3RAB9A | |
| SCHEMBL7464801 | 0.76 | FDPS (0.47) | FDPSCNR2ADORA3BRD4CREBBP | |
| SCHEMBL1251769 | 0.75 | CNR2 (0.53) | FDPSCNR2ADORA3RAB9ALMNA | |
| SCHEMBL28230042 | 0.75 | NPC1 (0.53) | FDPSCNR2ADORA3RAB9ALMNA | |
| SCHEMBL7599559 | 0.75 | FDPS (0.54) | FDPSCNR2ADORA3BRD4CREBBP | |
| SCHEMBL29825764 | 0.75 | FDPS (0.54) | FDPSCNR2ADORA3BRD4CREBBP | |
| SCHEMBL3800642 | 0.74 | SMN1; SMN2 (0.69) | FDPSADORA3RAB9ALMNA | |
| SCHEMBL4411955 | 0.73 | FDPS (0.53) | FDPSCNR2BRD4CREBBPRAB9A | |
| SCHEMBL2361181 | 0.73 | KDM4E (0.56) | FDPSCNR2BRD4CREBBPRAB9A | |
| SCHEMBL10051128 | 0.73 | FDPS (0.53) | FDPSCNR2ADORA3BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | FDPS 1269/4885ROCK1 4527/4885CNR2 119/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | FDPS 1269/4885ROCK1 4527/4885CNR2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.